GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Otonomy Inc (OTCPK:OTIC) » Definitions » Net Change in Cash

Otonomy (Otonomy) Net Change in Cash : $-41.70 Mil (TTM As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Otonomy Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Otonomy's Net Change in Cash for the three months ended in Sep. 2022 was $-13.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 was $-41.70 Mil.

Otonomy Net Change in Cash Historical Data

The historical data trend for Otonomy's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Otonomy Net Change in Cash Chart

Otonomy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.24 14.72 -8.43 5.57 46.65

Otonomy Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.25 -4.43 -14.54 -9.73 -13.00

Otonomy Net Change in Cash Calculation

Otonomy's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-42.418+55.963+33.1+0
=46.65

Otonomy's Net Change in Cash for the quarter that ended in Sep. 2022

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-13.011+0.01+0+0
=-13.00

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Otonomy Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Otonomy's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Otonomy (Otonomy) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Otonomy Inc (OTCPK:OTIC) » Definitions » Net Change in Cash
Comparable Companies
GLSI SESN OYST ANIX CTMX AXLA CLGN ETTX MYMD LPTX OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
4796 Executive Drive, San Diego, CA, USA, 92121
Website
https://www.otonomy.com
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.
Executives
Hogan H Michael Iii director C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Alan Charles Foster officer: Chief Scientific Officer 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Savel Robert Michael Ii officer: Chief Technical Officer 1025 OPAL WAY, VACAVILLE CA 95687
Paul E Cayer officer: CFO/Ch. Business Offcr & Sec. C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
David Allen Weber director, officer: President & CEO C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
Jill Marie Broadfoot director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ciara Kennedy director C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
James B Breitmeyer director
Eric J Loumeau officer: GC & Chief Compliance Officer C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Katherine Mary Bishop officer: Chief Scientific Officer C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Carl Lebel officer: Chief Scientific Officer 23256 MARIPOSA DE ORO, MALIBU CA 90265
Iain Mcgill director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Chau Quang Khuong director C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022